دورية أكاديمية
Bortezomib therapy in a real-world setting in patients with relapsed or refractory multiple myeloma
| العنوان: | Bortezomib therapy in a real-world setting in patients with relapsed or refractory multiple myeloma |
|---|---|
| المؤلفون: | Shang-Yi Huang, Tsai-Yun Chen, Ching-Yuan Kuo, Yeu-Chin Chen, Sheng-Fung Lin, Ming-Chih Chang, Xinzhu Lv, Betty Yang, Cheng-Shyong Chang |
| المصدر: | Oncology Reviews, Vol 13, Iss 1 (2019) |
| بيانات النشر: | Frontiers Media S.A., 2019. |
| سنة النشر: | 2019 |
| المجموعة: | LCC:Other systems of medicine LCC:Internal medicine |
| مصطلحات موضوعية: | Bortezomib, effectiveness, multiple myeloma, observational, real-world., Other systems of medicine, RZ201-999, Internal medicine, RC31-1245 |
| الوصف: | Bortezomib is a proteasome inhibitor, approved for treating newly diagnosed and relapsed multiple myeloma (MM). This realworld, multicenter, observational, non-interventional study of bortezomib was designed to collect and analyze prospective data in Taiwanese patients with relapsed or refractory MM. The primary endpoints included clinical effectiveness outcomes (disease response, disease progression [PD], time-to-response, time-toprogression, response duration, and overall survival [OS]). Secondary endpoints were safety and healthcare resource utilization. Total 100 patients (median [range] age 64.9 [37.0-85.5] years) were enrolled; 47 patients completed the study. Of the withdrawn patients (n=53), there were 48 deaths (PD-related death: n=35, adverse events [AEs]-related: n=12, other reason: n=1), and 5 due to loss to follow-up. Four patients in Cycle 1, 6 patients each in Cycle 2 and 5, 7 in Cycle 3, 10 patients in Cycle 4, 5 patients in Cycle 6, and 3 patients each in Cycle 7 and 8 achieved overall response during the study. Time-to-response was 4.68 months (95%CI: 3.2, NE) and response duration was 10.08 months (95%CI: 2.3, 28.6). Median OS was 9.8 months (95%CI: 3.8, 13.7), and median time-to-progression was 11.3 months (95%CI: 6.2, 20.2). Most common non-hematological AEs were diarrhea (n=32) and hypoesthesia (n=25); most common hematological AE was thrombocytopenia (n=18). Efficacy and safety profile of bortezomib in Taiwanese patients with MM was similar to global and other Asian population. Study provides a critical insight on use of bortezomib in realworld clinical practice, which can be helpful for Taiwanese healthcare providers’ decision-making processes. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 1970-5557 1970-5565 |
| Relation: | https://www.oncologyreviews.org/index.php/or/article/view/377; https://doaj.org/toc/1970-5557; https://doaj.org/toc/1970-5565 |
| DOI: | 10.4081/oncol.2019.377 |
| URL الوصول: | https://doaj.org/article/1d2c495198cc4729af7bf7c8c4354a95 |
| رقم الأكسشن: | edsdoj.1d2c495198cc4729af7bf7c8c4354a95 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 19705557 19705565 |
|---|---|
| DOI: | 10.4081/oncol.2019.377 |